Brown named Syapse chief medical officer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Thomas D. Brown was named chief medical officer at Syapse.

Brown joins Syapse from the Swedish Cancer Institute at Providence St. Joseph Health, where he served as executive director of SCI and led the establishment of the SCI Personalized Medicine Program. Brown also served in leadership roles across PSJH, including co-chair of the PSJH Cancer Leadership Council and co-chair of the PSJH Genomics Initiative.

Brown’s clinical and research efforts have been focused on gastrointestinal malignancies, broad developmental therapeutics in oncology, specifically phase I and II clinical trials, and health care policy and global medicine.

Prior to SCI, Brown served as professor of medicine and chief operating officer at the University of Arizona Cancer Center. He also spent a decade at MD Anderson Cancer Center, where he was a professor of medicine, and served as both deputy head and head ad interim of the Division of Cancer Medicine, as well as vice president for international programs.

While on the faculty at Duke University, Brown was one of the founding members of the multi-disciplinary GI cancer program, and of a southeast regional clinical trials consortium. Brown began his career as a faculty member at the University of Texas Health Science Center at San Antonio, working as a member of its phase I program, and serving as an executive officer within the Southwest Oncology Group where he was responsible for coordination of SWOG’s phase II portfolio.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login